3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Breast
1
Conditions
Breast Neoplasms
12
Triple Negative Breast Neoplasms
2
Prostatic Neoplasms
2
Neoplasms
2
Neoplasm Metastasis
2
Endometrial Neoplasms
2
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumors Harboring a BRAF V600 Mutation
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Melanoma
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
HER2 Negative Breast Cancer Not Immediately Operated
1
Glioma
1
Fallopian Tube Neoplasms
1
ER+ HER2- Advanced Breast Cancer
1
Diffuse Intrinsic Pontine Glioma
1
Colorectal Neoplasms
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Non-Small-Cell Lung
1
Breast Diseases
1
Anatomic Stage II Breast Cancer AJCC v8
1
Interventions
selpercatinib
2
pembrolizumab
2
abemaciclib
2
Pemetrexed
2
Nivolumab
2
Irinotecan
2
Fulvestrant
2
Abiraterone Acetate
2
ribociclib
1
repotrectinib
1
relatlimab
1
pralsetinib
1
pamiparib
1
palbociclib
1
osimertinib
1
onapristone
1
olaparib
1
glutathione pegylated liposomal doxorubicin
1
ficlatuzumab
1
exemestane
1
enzalutamide
1
elacestrant
1
cobimetinib
1
abiraterone
1
Trastuzumab
1
Taxes
1
Tamoxifen
1
STX-478
1
Radiation
1
RAD1901
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Neoplasms by Site
×
ribociclib
×
Clear all
NCT05768139
2026-05-22
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled